Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02833467 | Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA | unknown | — | 45 | Peking University People's HospitalOTHER | 0 | Aug 28, 2019 | clinicaltrials |
| NCT02759783 | Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases(CORE) | unknown | Phase 2 / Phase 3 | 245 | Royal Marsden NHS Foundation TrustOTHER | 2 | Aug 21, 2019 |
| clinicaltrials |
| NCT04029350 | Study of Anlotinib Combined With Osimertinib as Second-line Treatment in Stage IIIb-IV NSCLC With Confirmed EGFRm and T790M(ALTN-03) | unknown | Phase 2 | 53 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT04063449 | Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC | unknown | N/A | 170 | Dong WangOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT04063462 | Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 21, 2019 | clinicaltrials |
| NCT04059874 | Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate | unknown | Phase 1 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 16, 2019 | clinicaltrials |
| NCT03972189 | Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 111 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 15, 2019 | clinicaltrials |
| NCT04058704 | A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy(SMART) | unknown | Phase 3 | 296 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 15, 2019 | clinicaltrials |
| NCT01823003 | Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases(sbrtlungfff) | unknown | Phase 2 | 67 | Institut Català d'OncologiaOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT04037150 | Circulating DNA in Surgically Treated NSCLC | unknown | — | 100 | Helsinki University Central HospitalOTHER | 1 | Aug 6, 2019 | clinicaltrials |
| NCT03710616 | A Real-world Study to Explore Recurrence/Metastases of the NSCLC Patients and the Impact Factors of Patient Survivals | unknown | — | 700 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT04023617 | A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC | unknown | Phase 2 | 72 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jul 17, 2019 | clinicaltrials |
| NCT03334071 | Exercise Intervention During Chemotherapy in Advanced Lung Cancer Patients(EMBRACE) | unknown | N/A | 100 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT04007835 | Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI | unknown | N/A | 120 | Guangdong Association of Clinical TrialsOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT03553485 | Effects of VNS on RT-induced Inflammation and Prognosis of Patients With NSCLC | unknown | N/A | 12 | Vrije Universiteit BrusselOTHER | 1 | Jun 25, 2019 | clinicaltrials |
| NCT03992885 | Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations. | unknown | Phase 3 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 20, 2019 | clinicaltrials |
| NCT03987087 | A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC | unknown | Phase 2 | 68 | Guizhou Medical UniversityOTHER | 1 | Jun 14, 2019 | clinicaltrials |
| NCT03244605 | Efficacy Study of Comprehensive Rehabilitation Program in Postoperative NSCLC Patients | unknown | Phase 3 | 236 | Shanghai University of Traditional Chinese MedicineOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT03372694 | Efficacy Study of Comprehensive Rehabilitation Program Plus Chemotherapy in Postoperative NSCLC Patients | unknown | Phase 3 | 354 | Shanghai University of Traditional Chinese MedicineOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT03983811 | Adjuvant Chemotherapy With or Without Intercalated Icotinib | unknown | N/A | 174 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Jun 12, 2019 | clinicaltrials |
| NCT03726736 | Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC(ACWDVDFPTAN) | unknown | Phase 1 / Phase 2 | 97 | Yong FangOTHER | 1 | Jun 7, 2019 | clinicaltrials |
| NCT03062800 | Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003) | unknown | Phase 2 | 232 | Qilu Hospital of Shandong UniversityOTHER | 1 | Jun 5, 2019 | clinicaltrials |
| NCT03454685 | The Role of Microbiota on the Development of Lung Cancer | unknown | — | 100 | Xiaorong DongOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT03724604 | NSE/Alb as a Prognostic Biomarker for Lung Cancer(NARPBLC) | unknown | — | 202 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT03938012 | Evaluating Mutations in MET and TP53 Among Patients Diagnosed With Squamous Cell Carcinoma | unknown | — | 80 | National University Hospital, SingaporeOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03647956 | Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors | unknown | Phase 2 | 40 | The University of Hong KongOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03916913 | TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC | unknown | N/A | 85 | Chinese Academy of Medical SciencesOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03911193 | CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation(CABinMET) | unknown | Phase 2 | 25 | Fondazione Ricerca TraslazionaleOTHER | 1 | Apr 11, 2019 | clinicaltrials |
| NCT03905317 | Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene | unknown | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT03428022 | Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC(AFLC) | unknown | Phase 3 | 54 | Shenzhen People's HospitalOTHER | 1 | Apr 4, 2019 | clinicaltrials |
| NCT03903887 | A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 20 | Sun Yat-sen UniversityOTHER | 1 | Apr 4, 2019 | clinicaltrials |
| NCT02764606 | CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer(CANPOS) | unknown | — | 250 | Hospices Civils de LyonOTHER | 1 | Apr 2, 2019 | clinicaltrials |
| NCT03374280 | Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC | unknown | Phase 2 | 178 | Guangzhou Medical UniversityOTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT03886441 | Prevention of Locally Advanced NSCLC Radiotherapy Pneumonia by Inhaling Beclomethasone Propionate | unknown | Phase 2 | 194 | Tongji UniversityOTHER | 1 | Mar 26, 2019 | clinicaltrials |
| NCT03884192 | Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC(CONSIST) | unknown | Phase 3 | 162 | Shandong Cancer Hospital and InstituteOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT03874000 | Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients(SMART) | unknown | Phase 2 | 43 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT03871205 | Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer | unknown | Phase 1 | 30 | Shenzhen People's HospitalOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT03077854 | Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial | unknown | N/A | 64 | National Taiwan University HospitalOTHER | 1 | Mar 11, 2019 | clinicaltrials |
| NCT03856697 | Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation | unknown | Phase 3 | 406 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Feb 27, 2019 | clinicaltrials |
| NCT02771314 | Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC | unknown | Phase 2 | 48 | Hellenic Oncology Research GroupOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT03840408 | Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung Cancer | unknown | N/A | 1,753 | Shanghai 10th People's HospitalOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT02726568 | High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases | unknown | Phase 2 | 30 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 19, 2019 | clinicaltrials |
| NCT03300115 | Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC | unknown | Phase 2 | 222 | Hangzhou ACEA Pharmaceutical Research Co., Ltd.INDUSTRY | 1 | Feb 19, 2019 | clinicaltrials |
| NCT03838588 | The Tracking Molecular Evolution for NSCLC (T-MENC) Study | unknown | — | 200 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT03823807 | A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC | unknown | Phase 2 | 300 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 0 | Feb 1, 2019 | clinicaltrials |
| NCT03603262 | Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC | unknown | Phase 1 | 85 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT03811054 | The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 60 | Beijing Chest HospitalOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT02480634 | Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer | unknown | Phase 4 | 280 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Jan 16, 2019 | clinicaltrials |
| NCT03799094 | Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations | unknown | Phase 1 / Phase 2 | 150 | Clifford Hospital, Guangzhou, ChinaOTHER | 1 | Jan 10, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Aug 28, 2019source: clinicaltrials